

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** Confirmed

**Date and Time:** Wednesday, 11 March, 2015

**Venue:** **The Royal College of General Practitioners**  
**30 Euston Square**  
**NW1 2FB**

<b>Present:</b>	1. Chair, Dr Amanda Adler 2. Professor Ken Stein 3. Dr Ray Armstrong 4. Dr Jeff Aronson 5. Professor Keith Abrams 6. Professor John Cairns 7. Professor Imran Chaudhry 8. Mr Mark Chapman 9. Dr Lisa Cooper 10. Dr Neil Iosson 11. Dr Sanjay Kinra 12. Dr Miriam McCarthy 13. Professor Ruairidh Milne 14. Professor Stephen Palmer 15. Dr John Poundsford 16. Dr Danielle Preedy 17. Dr John Rodriguez 18. Mr Cliff Snelling 19. Dr Marta Soares 20. Dr Nicky Welton	Present for all notes Present for notes 1 to 17 Present for notes 1 to 17
-----------------	--	--

### **In attendance:**

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Elisabeth George	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Stuart Wood	Administrator, National Institute for Health and Care Excellence	Present for all notes

Carl Prescott	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 17
Eleanor Donegan	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 17
Miriam Brazzelli	Senior Research Fellow, Aberdeen HTA Group	Present for notes 1 to 15
Ewen Cummins	Health Economist, Aberdeen HTA Group	Present for notes 1 to 15
Mr David Chandler	Chief Executive of PAPAA nominated by Psoriasis and Psoriatic Arthritis Alliance	Present for notes 1 to 15
Ms Lucy Moorhead	Consultant Dermatologist nominated by British Association of Dermatologists	Present for notes 1 to 15
Dr Ruth Murphy	Professor of Dermatology and Therapeutics nominated by British Association of Dermatologists	Present for notes 1 to 15
Professor Catherine Smith	Clinical Nurse Specialist nominated by British Dermatological Nursing Group	Present for notes 1 to 15

**Non-public observers:**

Helen Barnett	NICE Editing Staff	Present for all notes
Heidi Livingstone	NICE PIP Staff	Present for all notes
Joost De Falter	NICE CHTE Staff	Present for all notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of secukinumab for treating moderate to severe plaque psoriasis.
2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Heidi Livingstone and Joost De Falter.

3. Apologies were received from: Matt Campbell-Hill, Professor Daniel Hochhauser, Mrs Anne Joshua, Dr Rebecca Kearney, Chris O'Regan, Alun Roebuck, Dr Sanjeev Patel, Dr Nerys Woolacott

## **Any other Business**

4. The Committee were given an update on the timings of future appraisals.

## **Notes from the last meeting**

5. Minutes from the 10 February committee meeting were approved

## **Appraisal of secukinumab for treating moderate to severe plaque psoriasis**

### **Part 1 – Open session**

6. The Chair welcomed the invited experts: Mr David Chandler, Ms Lucy Moorhead, Dr Ruth Murphy and Professor Catherine Smith to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Novartis to the meeting.
8. The Chair asked all Committee members to declare any relevant interests

Chair, Dr Amanda Adler, Vice Chair, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor Keith Abrams, Professor John Cairns, Professor Imran Chaudry, Mr Mark Chapman, Dr Lisa Cooper, Dr Neil Iosson Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Professor Stephen Palmer, Dr John Poundsford, Dr Danielle Preedy, Dr John Rodriguez, Alun Roebuck, Cliff Snelling, Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of secukinumab for treating moderate to severe plaque psoriasis.

- 8.1. Chris O'Regan was absent from this meeting due to a conflict. His employer Merck, Sharp and Dohme manufactures and promotes Remicade (infliximab) which has an indication for psoriasis. Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.
9. The Chair asked all NICE Staff to declare any relevant interests.
  - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of secukinumab for treating moderate to severe plaque psoriasis.
10. The Chair asked the Evidence Review Group representatives and the invited experts to declare their relevant interests.

- 10.1. Lucy Moorhead declared a personal non-specific pecuniary interest as the organisation that nominated her receives grants from the pharmaceutical industry.
  - 10.1.1. It was agreed that this declaration would not prevent Lucy Moorhead from participating in this section of the meeting
- 10.2. Dr Ruth Murphy declared a personal non-specific pecuniary interest as she has attended advisory boards for the company involved in this appraisal.
  - 10.2.1. It was agreed that this declaration would not prevent Dr Ruth Murphy from participating in this section of the meeting
- 10.3. Professor Catherine Smith declared a personal non-specific pecuniary interest as she is the principal investigator in the ongoing secukinumab trial.
  - 10.3.1. It was agreed that this declaration would not prevent Professor Catherine Smith from participating in this section of the meeting

11. The Chair introduced the lead team, Professor Keith Abrams, Dr Neil Iosson and Mr Cliff Snelling who gave presentations on the clinical effectiveness and cost effectiveness of secukinumab for treating moderate to severe plaque psoriasis
12. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of secukinumab for treating moderate to severe plaque psoriasis on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:
  - 12.1. The direct evidence for the effectiveness of secukinumab compared with placebo and etanercept
  - 12.2. The network meta-analysis evidence for the effectiveness of secukinumab compared with all comparators
  - 12.3. The generalisability of the clinical evidence
  - 12.4. Whether there were any relevant subgroups
  - 12.5. The plausibility of the health economic model, including its structural and parameter assumptions
  - 12.6. The most appropriate source of resource use data for best supportive care in the model
  - 12.7. The quality of life data in the model
  - 12.8. Whether secukinumab represented a step-change in the management of psoriasis
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
15. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

16. The Committee instructed the technical team to prepare the guidance document in line with their decisions.

## **Date, time and venue of the next meeting**

17. Tuesday 14 April 2015 at Prospero House, 241 Borough High Street, SE1 1GA